Medicare

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Hackensack Meridian Health and Lumeris Expand Value-Based Partnership to Include Traditional Medicare Through MSSP ACO

Collaboration builds on high-performing Clinically Integrated Network for Commercial and Medicare Advantage to improve outcomes and care coordination for New...

Cheelcare Announces Medicare and Medicaid Services Reimbursement Approval for Companion Power Assist Device, Expanding U.S. Market Access

Investment Highlights:U.S. Medicare and Medicaid reimbursement eligibility achieved:The Company has received Pricing, Data Analysis, and Coding ("PDAC") verification, enabling U.S....

Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the...

BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business

Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks,...

error: Content is protected !!